Plus therapeutics reports positive clinical outcomes from respect-gbm trial at the society of nuclear medicine and molecular imaging (snmmi) 2022 annual meeting

Data validates continued high radiation absorbed of 186 rnl in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure
PSTV Ratings Summary
PSTV Quant Ranking